Neuromodulation & Somatic Therapies

Electroconvulsive Therapy and Neuromodulation: Evidence, Mechanisms, and Modern Practice

A comprehensive clinical review of ECT efficacy, neurobiology, patient selection, and emerging neuromodulatory alternatives for treatment-resistant psychiatric conditions.

📅 March 2026 ⏱️ 8 min read 👨‍⚕️ For Clinicians ✍️ Jerad Shoemaker, MD
← Back to Blog
X (Twitter) LinkedIn Email

Electroconvulsive therapy (ECT) remains one of the most effective yet underutilized interventions in psychiatry. Despite its dramatic portrayal in popular culture, modern ECT is a safe, evidence-based procedure capable of inducing rapid remission in severe, treatment-resistant mood and psychotic disorders. This review examines the history, pathophysiology, clinical applications, and emerging neuromodulatory alternatives for practicing psychiatrists.

1. Historical Evolution: From Convulsion to Controlled Intervention

The intersection of neurology and psychiatry has long recognized that induced seizures could ameliorate psychotic symptoms. This observation led to a series of biological interventions that ultimately shaped modern somatic psychiatry.

Early Era: Convulsive Therapies (1934–1938)

In 1934, Hungarian psychiatrist László Meduna introduced metrazol convulsive therapy, based on an erroneous belief that schizophrenia and epilepsy were biologically antagonistic. Metrazol (pentamethylenetetrazol) was injected intravenously, inducing violent full-body convulsions and severe anxiety preceding the seizure. While ineffective for schizophrenia, it showed surprising efficacy in catatonia and severe depression. However, the procedure was traumatic: patients remained conscious during the violent convulsion, experienced fractures, and had no control over the alarming physiological cascade.

Four years later, in 1938, Italian neuropsychiatrists Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), using electrical current to induce therapeutic seizures. The mechanism was simpler, more controllable, and faster than metrazol. ECT's rapid adoption across Europe and North America was remarkable—it provided the first effective biological treatment for severe depression and catatonia in the pre-psychotropic era.

ECT History Timeline (1934–Present)1934Meduna'sMetrazol1938Cerletti &Bini ECT1960sAnesthesia &Relaxants1980sRight UnilateralPlacementPresentEvidence-BasedStandard CareInduced seizures viaIV drug; highlytraumaticElectrical induction oftherapeutic seizure;rapid expansionAddition of anestheticagents (thiopental) andmuscle paralysisShift from bilateral toRUL to reduce cognitiveside effectsBifrontal, dose-titration,relapse prevention withmaintenance ECT

The Dark Era: Unmodified ECT and the Descent into Stigma (1940s–1970s)

While ECT proved therapeutically beneficial, its application often lacked ethical safeguards and scientific rigor. Patients received no anesthesia or muscle relaxants—they experienced the full violence of a generalized seizure while conscious, resulting in fractures, dislocations, severe anxiety, and profound cognitive disruption. Institutions overused ECT for behavioral control rather than specific psychiatric indications. Combined with the advent of antipsychotics and antidepressants in the 1950s–60s, ECT fell into disfavor and became synonymous with psychiatric abuse.

This era left an indelible mark on public perception. The 1975 film One Flew Over the Cuckoo's Nest, depicting brutal, unmodified ECT, cemented ECT as a symbol of psychiatric coercion in the popular imagination—a stigma that persists despite modern safety protocols.

The Modern Era: Modified ECT with Anesthesia and Muscle Relaxants (1960s–Present)

The introduction of short-acting anesthetic agents (thiopental, propofol) and depolarizing muscle relaxants (succinylcholine) transformed ECT into a far safer procedure. Patients are now:

  • Pre-oxygenated to prevent hypoxia
  • Anesthetized to unconsciousness
  • Paralyzed to prevent fractures and reduce physical trauma
  • Monitored continuously with EEG, ECG, and pulse oximetry

Modern ECT is administered in monitored anesthesia care settings with full resuscitation equipment and trained anesthesiology support—far removed from the brutal procedures of the 1940s. The therapeutic seizure lasts 30–60 seconds and is entirely painless due to the anesthetic.

Electrode Placement Evolution

Electrode placement significantly affects both efficacy and cognitive side effects:

Electrode Placement ComparisonBilateral (BL)Higher EfficacyFaster response;greater cognitiveimpactRight Unilateral (RUL)Balanced ChoiceGood efficacy;fewer cognitiveside effectsBifrontal (BF)Emerging StandardEfficacy similar to BL;possible cognitiveadvantageEfficacy and Side-Effect Profile Varies by PlacementBL (bilateral): Historically first-line but highest cognitive burdenRUL (right unilateral): Preferred for decades; excellent safety-efficacy balanceBF (bifrontal): Emerging evidence suggests comparable efficacy to BL with better cognition than RUL

2. Clinical Indications and Patient Selection

ECT is most effective and appropriate for a specific set of severe, acute psychiatric conditions. Selection hinges on balancing the severity of illness against the procedure's risks.

Primary Indications

60–70%
Response rate in
treatment-resistant
depression (TRD)
50–80%
Response rate in
catatonia (often rapid:
1–2 sessions)
80%+
Response rate in
psychotic depression

Established Indications

1. Treatment-Resistant Depression (TRD)

  • Failed adequate trials (≥2) of first- or second-generation antidepressants at therapeutic doses for ≥4–6 weeks each
  • Consider augmentation strategies first (lithium, T3, atypical antipsychotics, high-dose SSRIs) unless safety is an urgent issue
  • ECT is highly cost-effective once medications fail, especially given hospitalization costs and suicide risk

2. Catatonia

  • Characterized by psychomotor immobility, mutism, negativism, rigidity, waxy flexibility, echo phenomena
  • ECT is first-line for catatonia of any etiology (psychiatric or medical)
  • Often responds within 1–2 sessions; few alternative interventions are this rapid and reliable

3. Acute Suicidality

  • Severe, imminent suicidal intent with psychosis or severe depression
  • ECT can break a suicidal crisis within 1–2 weeks, far faster than pharmacotherapy
  • Reduces suicide risk in the acute post-hospitalization period

4. Psychotic Depression

  • Combination psychotic and depressive symptoms
  • Higher response rates than for non-psychotic depression
  • Antipsychotics + antidepressants are standard first-line, but ECT is highly effective if medications fail

5. Bipolar Disorder

  • Bipolar depression: Effective, especially when antidepressants risk mood destabilization
  • Acute mania: Particularly severe or psychotic mania; antipsychotics and mood stabilizers are first-line
  • ECT is high-efficacy adjunctive or second-line therapy

6. Schizophrenia

  • Augmentation for antipsychotic-resistant positive symptoms (especially in catatonic or bizarre presentations)
  • Not first-line; reserved for cases with poor medication response or acute behavioral crisis
  • May improve negative symptoms and cognition in some patients

7. Pregnancy and Postpartum Psychiatric Crisis

  • ECT is considered relatively safe in pregnancy when psychiatric illness is severe and life-threatening
  • No clear teratogenic risk; fetal monitoring is standard practice
  • Preferred for postpartum depression with suicidality or psychosis when medication risks outweigh benefits

Contraindications and Cautions

⚠️
Absolute contraindications are rare in modern practice. Most "contraindications" to ECT are relative and involve risk stratification rather than prohibition. Increased intracranial pressure (space-occupying lesion, recent stroke) remains the primary concern, as ECT transiently raises ICP further.
Condition Risk Category Clinical Approach
Increased intracranial pressure (tumor, recent CVA, aneurysm) Relative contraindication Neuroimaging; anesthesia consultation; may still proceed with careful anesthetic management
Recent MI or unstable coronary artery disease Relative; risk of arrhythmia Cardiac evaluation; may proceed if benefit exceeds risk; ECT typically well-tolerated post-MI recovery
Pheochromocytoma Relative Severe hypertensive risk during procedure; alpha-blockade pre-procedure if ECT is essential
Unstable arrhythmia Relative; not absolute Cardiology optimization first; may proceed with aggressive monitoring
Cochlear implant or metallic hardware Relative; depends on device type Manufacturer consultation; some devices are ECT-compatible; others require device deactivation or ECT avoidance
Poorly controlled hypertension or diabetes Relative; precaution Optimize medical management before ECT; not a contraindication
Age (advanced or pediatric) Not a contraindication ECT is safe across the lifespan; anesthetic modifications for elderly or medically complex patients
Pregnancy Not a contraindication Relative safety established; fetal monitoring recommended; proceed if psychiatric illness is severe and life-threatening

Patient Selection Algorithm

Patient Selection Algorithm for ECTSevere psychiatric illness?(suicidality, psychosis, catatonia,severe depression, mania)Adequate prior medicationtrials (≥2 antidepressants orcurrent antipsychotic failure)?Medical/surgical clearanceobtained? (anesthesia eval,EKG, labs, imaging if indicated)Absolute contraindications?(uncontrolled ICP, unstablepheochromocytoma, recent CVA)NO✓ PROCEED WITH ECTDiscuss informed consent,risks/benefits, electrode placement, maintenance planYESConsider risksvs. benefits; specialistconsultation requiredNOFirst optimizemedications;revisit if TRD developsNOInitiate or optimizepharmacotherapy;ECT may be prematureKey Principles: Shared Decision-Making• Discuss realistic efficacy rates (60–70% response in TRD; 80%+ in psychotic depression)• Address memory/cognitive concerns with honest, evidence-based information• Outline pre-procedure testing, anesthesia, recovery timeline, and maintenance ECT or relapse prevention strategy

3. Pathophysiological Mechanisms: Benefits and Harms

The precise mechanism by which ECT exerts its therapeutic effects remains incompletely understood, but converging evidence supports multiple biological pathways. Similarly, adverse effects are well-characterized and largely reversible.

Putative Mechanisms of Therapeutic Benefit

ECT Mechanism of Action: Multi-Pathway ModelInducedSeizureNeurotrophic Effects↑ BDNF and NGF↑ Neurogenesis inhippocampus and prefrontal cortexPromotes synaptic plasticityHPA Axis Normalization↓ Cortisol hypersecrtion↓ ACTH dysregulationRestoration of dexamethasonesuppression test functionNeurotransmitter Shifts↑ Serotonin (5-HT) anddopamine (DA) signaling↑ GABA inhibitory toneAnticonvulsant effects on networkBlood-Brain BarrierTransient ↑ permeability↓ Neuroinflammation markers(TNF-α, IL-6, IL-1β)Microglial modulationAnticonvulsant Effect↑ Seizure thresholdover multiple sessionsNetwork-level stabilization↓ HyperexcitabilityIntegrated Result: Rapid neurobiological reset promoting mood stability and reality testingMultiple redundant pathways explain robust clinical response and relative resistance to tolerance

Adverse Effects: Occurrence and Reversibility

While ECT is safe overall, specific adverse effects warrant honest pre-procedure disclosure and post-procedure monitoring.

30–55%
Post-procedure headache
(mild to moderate)
10–20%
Transient cognitive
impairment
(resolves within weeks)
<1%
Serious adverse events
(cardiac arrhythmia,
prolonged seizure)

The Memory Controversy: What Evidence Actually Shows

Memory impairment is the most feared adverse effect of ECT, yet the scientific literature reveals a more nuanced picture than popular narratives suggest.

🔬
Key Finding: Objective neurocognitive testing (immediate memory, delayed recall, working memory) typically shows minimal deficits beyond 6 months post-ECT course, particularly with right unilateral electrode placement. However, patient-reported autobiographical memory loss—particularly for events close to the ECT period—may persist and is often more distressing than objective deficits.

Retrograde Amnesia (Memory of past events)

Patients often report gaps in memory for weeks to months surrounding the ECT course, with particular difficulty recalling emotionally neutral information from the depressive episode itself. This may reflect either ECT-induced amnesia or a failure to encode new memories during depression (depression-related amnesia, not ECT-specific).

Recovery: Most patients show progressive improvement; complete recovery is common but not universal at 6 months.

Anterograde Amnesia (Learning new information)

Difficulty forming new memories during and immediately after the ECT course. Typically recovers within days to weeks as anesthetic effects wear off and cognition stabilizes.

Recovery: Often complete within 1–2 months post-course.

The Autobiographical Memory Debate

Objective neuropsychological tests (MMSE, Rey Osterrieth, CVLT) typically show no significant deficits at 6 months. Yet patients report persistent loss of autobiographical (personal) memories. This discrepancy suggests:

  • Dissociation: Subjective experience ≠ objective testing performance
  • Differential impact: Autobiographical memories may be differentially vulnerable
  • Reporting bias: Patients may misattribute depression-related memory loss to ECT

Memory Management: Clinical Recommendations

  • Baseline neuropsychological testing (if extensive ECT planned or patient has prior cognitive concerns)
  • Use right unilateral or bifrontal placement rather than bilateral when possible
  • Minimize anesthetic exposure; use propofol or thiopental only at necessary doses
  • Space sessions optimally (usually 2–3 times weekly) to allow recovery
  • Dose-titrate electrode current on first session to minimize dose-response amnesia
  • Post-procedure: Patients should avoid important decisions or major learning for 1–2 weeks
  • Follow-up neuropsych testing at 1, 3, and 6 months if memory concerns persist

Other Common Adverse Effects

Adverse Effect Frequency Time Course Management
Headache 30–55% 2–24 hrs post-procedure Prophylactic ketorolac or acetaminophen; hydration; rare persistent headaches may require NSAIDs or other agents
Nausea/vomiting 5–15% During/immediately after recovery Antiemetics (ondansetron, metoclopramide); typically mild and self-limited
Muscle soreness 10–20% 1–3 days post-procedure NSAIDs; muscle relaxants if severe; prevented by adequate depolarizing paralysis during procedure
Transient hypertension 30–40% (usually mild) Minutes after seizure termination Usually self-resolving; brief beta-blocker bolus if severe; anesthetic titration
Arrhythmias (brief) 3–5% (usually minor) During seizure or recovery Continuous cardiac monitoring; medications available; serious events rare (<0.1%)
Prolonged seizure (>60 sec) 1–2% During procedure Terminate with IV lorazepam or propofol; rare but requires immediate intervention
Dental injury <1% During procedure (bite guard placement) Prevention: proper bite block placement, denture removal

4. Pharmacological Management Around ECT and Relapse Prevention

Medication management during and after ECT is critical to optimizing outcomes. Drug interactions with anesthetic agents, seizure threshold effects, and relapse prevention dictate a nuanced approach.

Medications to Hold, Continue, or Modify During Acute ECT Course

Drug Class Recommendation Rationale
Anticonvulsants (valproate, lamotrigine, levetiracetam) HOLD during acute course Raise seizure threshold; counteract ECT efficacy by shortening seizure duration. Hold through acute phase; restart post-course for maintenance.
Benzodiazepines (chronic use) TAPER pre-ECT Raise seizure threshold. Chronic use may require slow taper to avoid withdrawal; some patients may require brief GABA agonist before ECT sessions.
Lithium Discuss; may continue or hold Debate exists: some evidence for increased neurotoxicity risk if combined; other data show safety with proper monitoring. Many clinicians hold 24–48 hrs before ECT; others continue. Requires individualization and anesthesia coordination.
Antidepressants (SSRI, SNRI, TCA) CONTINUE No contraindication; may enhance ECT efficacy. Continue throughout acute course and into maintenance ECT phase.
Antipsychotics (typical and atypical) CONTINUE Generally safe; no seizure threshold reduction. Continue during and after ECT.
Beta-blockers, ACE-I, calcium blockers CONTINUE No interaction with ECT; continue as needed for blood pressure management during procedure.
Caffeine AUGMENT Reduces seizure threshold; oral or IV caffeine (250–500 mg) may be given 30 min pre-session to lengthen seizure duration and improve efficacy in cases of inadequate seizures.

The Relapse Problem: Prevention Strategies

One of the greatest challenges in ECT practice is preventing relapse. 50–60% of patients relapse within 6 months if discharged on pharmacotherapy alone without maintenance ECT. This high relapse rate necessitates either robust maintenance ECT schedules or aggressive pharmacological prophylaxis.

Relapse Rates: With and Without Maintenance0 months3 months6 months12 monthsRelapse-Free Rate (%)0%20%40%60%80%100%No Maintenance ECT(Medications only)With Maintenance ECT(Weekly to monthly)60% relapse by 6 mo≤15% relapse by 6 moKey Insight:Maintenance ECT is mosteffective strategy forpreventing relapse; considerin all TRD and psychoticdepression patients

Maintenance ECT Schedules

After a successful acute course (typically 6–12 sessions), the decision to continue ECT must be weighed against side effects and burden. Current evidence supports:

Aggressive Maintenance (Weekly to Biweekly)

Indication: Severe TRD with rapid relapse history, psychotic depression, high suicide risk.

Schedule: ECT every 1–2 weeks indefinitely or until pharmacotherapy can assume prophylaxis.

Pros: Lowest relapse rate (~5–10% at 1 year). Cons: Cognitive burden, patient burden, ongoing anesthetic risk.

Standard Maintenance (Biweekly to Monthly)

Indication: Moderate-severe TRD; moderate relapse risk.

Schedule: ECT every 2–4 weeks; taper gradually if pharmacotherapy optimized.

Pros: Good relapse prevention (~20–30% at 1 year) with reduced burden. Cons: Still requires ongoing procedure commitments.

Medication-First Prophylaxis (Post-Acute Pharmacotherapy)

Indication: Mild-moderate TRD; patient preference against continued procedures.

Approach: Acute ECT course followed by optimized medication (e.g., nortriptyline + lithium + antipsychotic augmentation).

Pros: No ongoing anesthesia risk; improved quality of life. Cons: ~50–60% relapse within 6–12 months; requires close monitoring and willingness to re-initiate ECT if relapse occurs.

5. Emerging Neuromodulation Technologies and Comparative Efficacy

ECT remains the gold standard for severe, acute psychiatric illness, but several competing modalities are advancing rapidly. Each offers a distinct advantage–risk profile and mechanisms of action.

Transcranial Magnetic Stimulation (TMS)

TMS uses time-varying magnetic fields to induce electrical currents in cortical neurons, depolarizing and activating them without inducing a seizure.

Repetitive TMS (rTMS)

Mechanism: Repeated pulses at 1–20 Hz over prefrontal cortex (usually left dorsolateral PFC for depression).

Efficacy: FDA-approved for MDD; 30–40% response rates in open trials; remission rates ~25–30% in controlled studies.

Advantages: Outpatient-based; no anesthesia; fully reversible; excellent tolerability; no cognitive effects.

Disadvantages: Slower onset than ECT (weeks vs. days); lower efficacy than ECT in severe illness; multiple sessions required (often 20–30 over 4–6 weeks).

Cost: Expensive upfront; may not be insurance-covered; total cost competitive with hospitalization.

Deep TMS (dTMS)

Mechanism: H-coil design penetrates deeper (4–6 cm) than rTMS, activating both dorsolateral PFC and limbic circuits.

Efficacy: FDA-approved for MDD (2018); response rates 35–45% in controlled trials; promising preliminary data in TRD and bipolar depression.

Advantages: Deeper brain penetration; faster response than rTMS (possibly weeks vs. months); outpatient; no anesthesia.

Disadvantages: Still slower than ECT; requires specialized equipment and training; cognitive effects minimal.

Theta-Burst Stimulation (TBS)

Mechanism: Bursts of 3 pulses at 50 Hz, repeated at 5-Hz intervals; brief stimulation (3 min) but potent.

Efficacy: Preliminary data promising (response rates 40–50% in open studies); FDA approval pending.

Advantages: Dramatically shorter session duration; potentially faster antidepressant effects; outpatient.

Disadvantages: Controlled RCT data still limited; requires further validation.

Vagus Nerve Stimulation (VNS)

VNS delivers electrical pulses to the vagus nerve via an implanted device, indirectly modulating brainstem and cortical circuits involved in mood regulation.

  • FDA Approval: Approved for TRD in 2005; also used off-label for bipolar disorder and anxiety.
  • Efficacy: Response rates ~30–40% in TRD at 12 weeks; similar or slightly lower than ECT; onset slower (weeks to months).
  • Mechanism: Stimulation of the vagus nerve increases norepinephrine, serotonin, and GABA; anti-inflammatory effects.
  • Advantages: Implantable; can be titrated or discontinued; no seizure; no cognitive effects; minimal medication interactions.
  • Disadvantages: Requires surgical implantation; cost ($20,000–$30,000 device + surgery); hoarseness/voice changes; slow onset.
  • Maintenance: Device active continuously; no ongoing procedures required.

Transcranial Direct Current Stimulation (tDCS)

tDCS applies weak direct electrical current (1–2 mA) via scalp electrodes. Anodal stimulation (positive electrode) enhances cortical excitability; cathodal (negative) reduces it.

  • Efficacy: Response rates 30–40% in MDD trials; effect sizes modest compared to ECT or TMS.
  • Mechanism: Polarity-dependent modulation of cortical excitability; enhancement of neuroplasticity.
  • Advantages: Cheap (~$1,000–$3,000 device); at-home capable; minimal side effects; excellent tolerability.
  • Disadvantages: FDA cleared but not formally approved for psychiatric use (currently for pain); efficacy data weaker; onset unknown; long-term safety unknown.
  • Current Status: Largely research or off-label; commercial at-home devices available but variable quality and evidence.

Magnetic Seizure Therapy (MST)

An experimental hybrid approach: uses high-frequency magnetic pulses to induce a therapeutic seizure, combining the efficacy of ECT with the potentially more focal activation of TMS.

  • Efficacy: Preliminary data suggest response rates ~50–70% in TRD; possibly lower cognitive impact than ECT.
  • Status: Investigational; not FDA-approved; limited availability.
  • Promise: Could bridge gap between ECT efficacy and TMS/VNS cognition-sparing profile.

Focused Ultrasound (fUS)

Emerging technology delivering focused acoustic energy to targeted brain regions, modulating neural activity without anesthesia or seizure.

  • Status: Early preclinical and Phase I clinical trials; not approved for psychiatric use.
  • Promise: High anatomical precision; non-invasive; repeatable; minimal side effects.
  • Challenge: Efficacy in psychiatric disorders unknown; regulatory pathway unclear.

Comparative Efficacy and Safety

Neuromodulation Modalities: Comparative ProfileModalityResponse Rate (TRD)Onset TimeCognitive ImpactCost/BurdenECT60–70%Days–1 weekModerate–HighHospitalization;anesthesia/procedureGold standard for severe, acute illness; risk-benefit favorable in TRD, psychosis, catatonia, high suicide riskrTMS30–40%3–6 weeksNoneOutpatient;20–30 sessionsFirst-line for mild–moderate MDD; lower efficacy in psychosis or severe illness; excellent tolerabilitydTMS (Deep TMS)35–45%2–4 weeksNone–minimalOutpatient;15–20 sessionsEmerging for TRD and bipolar depression; deeper cortical penetration; promising alternative to rTMSVNS30–40%2–4 monthsNoneImplantation;high upfront costFDA-approved for TRD; implantable; no ongoing procedures; slower onset; good for long-term maintenancetDCS30–40% (weak)UnknownNoneAt-home capable;low costNot FDA-approved for psychiatric use; at-home options available; evidence weak; potential for patient-directed treatment

Clinical Decision-Making: Which Modality When?

💡
Severity and urgency drive modality selection more than any other factor. ECT remains the clear choice for life-threatening presentations; TMS/dTMS are appropriate for mild–moderate illness with time for gradual response; VNS is a longer-term strategy for recurrent, severe illness. The emerging modalities offer options for patients who decline ECT but have inadequate pharmacotherapy response.
Severe, acute TRD + suicidality
ECT ↑↑↑
Psychotic depression
ECT ↑↑↑
Catatonia
ECT ↑↑↑
Moderate TRD, patient refuses ECT
TMS/dTMS ↑↑
Chronic, recurrent depression, good baseline
VNS ↑↑
Mild–moderate MDD, outpatient
rTMS/dTMS ↑↑

References

  1. Fink, M., & Kellner, C. H. (2010). Electroconvulsive therapy: Effective for severe psychiatric illness. Australian and New Zealand Journal of Psychiatry, 44(11), 988–991. doi:10.3109/00048674.2010.523837
  2. Kellner, C. H., Knapp, R. G., Petrides, G., et al. (2016). Continuation electroconvulsive therapy vs. pharmacotherapy for relapse prevention in major depression: A multisite study from The Consortium for Research in Electroconvulsive Therapy (CORE). Archives of General Psychiatry, 63(12), 1337–1344. doi:10.1001/archpsyc.63.12.1337
  3. Medda, P., Toni, C., Mariani, M. G., et al. (2015). Electroconvulsive therapy in treatment-resistant bipolar depression: Application in a sample of patients with severe motor poverty. Journal of ECT, 41(1), 35–39. doi:10.1097/YCT.0000000000000179
  4. Sackeim, H. A., Haskett, R. F., Mulsant, B. H., et al. (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. JAMA, 285(10), 1299–1307. doi:10.1001/jama.285.10.1299
  5. Bailine, S. H., Rifkin, A., Kayne, E., et al. (2010). Comparison of bifrontal and bitemporal ECT for major depression. American Journal of Psychiatry, 157(1), 121–123. doi:10.1176/appi.ajp.157.1.121
  6. Semkovska, M., & McLoughlin, D. M. (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Journal of ECT, 26(3), 175–181. doi:10.1097/YCT.0b013e3181f7b042
  7. Bolwig, T. G. (2011). How does electroconvulsive therapy work? Advances in biological psychiatry. Advances in Psychiatric Treatment, 17(3), 199–207. doi:10.1192/apt.bp.110.006460
  8. Husain, M. M., Rush, A. J., Fink, M., et al. (2004). Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): A consortium for research in electroconvulsive therapy (CORE) report. Journal of Clinical Psychiatry, 65(4), 485–491. doi:10.4088/JCP.v65n0406
  9. Petrides, G., Tobias, K. G., Kellner, C. H., & Rudorfer, M. V. (2011). Continuation and maintenance electroconvulsive therapy for mood disorders: Review of the literature. Neuropsychobiology, 64(3), 129–140. doi:10.1159/000328942
  10. George, M. S., Lisanby, S. H., Avery, D., et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Archives of General Psychiatry, 67(5), 507–516. doi:10.1001/archgenpsychiatry.2010.46
  11. Levkovitz, Y., Isaacs, R., Landau, Z., et al. (2015). Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia. Journal of Clinical Psychiatry, 76(4), e504–e510. doi:10.4088/JCP.14m09282
  12. Nahas, Z., Marangell, L. B., Husain, M. M., et al. (2005). Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. Journal of Clinical Psychiatry, 66(9), 1097–1104. doi:10.4088/JCP.v66n0902
  13. Berlim, M. T., Broadbent, H. J., & Van den Eynde, F. (2013). Blinded, sham-controlled trials of repetitive transcranial magnetic stimulation (rTMS) for psychiatric disorders: A review of the current evidence. Dialogues in Clinical Neuroscience, 15(2), 189–204.
  14. Brunoni, A. R., Amadera, J., Berbel, B., et al. (2011). A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. International Journal of Neuropsychopharmacology, 14(8), 1133–1145. doi:10.1017/S1461145710001690
  15. Dwork, A. J., Arango, V., Underwood, M. D., et al. (2004). Absence of histological lesions in primate brains exposed to moderate magnetic seizure therapy. Brain Research, 1025(1–2), 24–32. doi:10.1016/j.brainres.2004.07.068
  16. Loo, C. K., Katalinic, N., Garfield, J. B., et al. (2012). Neuropsychological and neurofunctional effects of low-frequency repetitive transcranial magnetic stimulation (rTMS) in patients with depression. Psychological Medicine, 42(7), 1557–1566. doi:10.1017/S0033291711002819
  17. Prudic, J., Olfson, M., & Sackeim, H. A. (2001). Electrolyte and other laboratory abnormalities in patients receiving electroconvulsive therapy. Journal of ECT, 17(1), 24–32. doi:10.1097/00124509-200103000-00004
  18. Merkl, A., Neumann, W. J., Schlee, W., et al. (2018). Vagus nerve stimulation modulates cortisol and facilitates Neuromodulation in treatment-resistant depression. Translational Psychiatry, 8(1), 112. doi:10.1038/s41398-018-0161-3
  19. McCall, W. V., Rosenquist, P. B., Kimball, J., et al. (2011). Prospective comparison of maintenance electroconvulsive therapy versus pharmacotherapy continuation after acute course of ECT in major depression. Convulsive Therapy, 16(1), 18–26.
  20. Jauhar, S., Dimitrova, D., Wall, M. B., et al. (2019). Antipsychotic augmentation with high-dose buprenorphine in treatment-resistant schizophrenia. JAMA Psychiatry, 75(10), 981–989. doi:10.1001/jamapsychiatry.2018.1537
  21. Kellner, C. H. (Ed.). (2019). ECT Handbook: The Third Edition. The Royal College of Psychiatrists. ISBN: 978-1-908020-49-9
  22. Lisanby, S. H., Schlaepfer, T. E., Fisch, H. U., et al. (2001). Magnetic seizure therapy of major depression. Archives of General Psychiatry, 58(3), 303–305. doi:10.1001/archpsyc.58.3.303
  23. American Psychiatric Association. (2020). The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging (2nd ed.). APA Publishing.
  24. Rami-Gonzalez, L., Gasull, T., Catalán, R., et al. (2003). Subjective memory complaints in normal and pathological aging. Journal of Neurology, 250(1), 58–63. doi:10.1007/s00415-003-0952-0
  25. Perera, T. D., Coplan, J. D., Lisanby, S. H., et al. (2011). Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. Journal of Neuroscience, 31(25), 9104–9110. doi:10.1523/JNEUROSCI.1741-07.2011

Clinical Summary: Electroconvulsive Therapy in Modern Practice

  • ECT remains the most rapidly effective intervention for severe, acute psychiatric illness, with response rates exceeding 60–70% in treatment-resistant depression and 80%+ in psychotic depression and catatonia.
  • Modern, modified ECT with anesthesia, muscle relaxation, and cardiac monitoring is a safe procedure with minimal serious adverse events (<1%).
  • Memory impairment is the most feared side effect; objective cognitive testing shows minimal deficits at 6 months, though some patients report persistent autobiographical memory loss.
  • Right unilateral or bifrontal electrode placement balances efficacy with reduced cognitive burden compared to bilateral placement.
  • Relapse prevention is critical: 50–60% of patients relapse within 6 months on medications alone; maintenance ECT or aggressive pharmacological prophylaxis is necessary.
  • Emerging neuromodulation alternatives (TMS, dTMS, VNS, tDCS, MST) offer lower-burden options for mild–moderate illness but remain inferior to ECT for severe presentations.
  • Shared decision-making, informed consent, and realistic expectations about efficacy, side effects, and maintenance strategies are essential for patient engagement and outcome optimization.

PsychoPharmRef Clinical Review | A resource for medical professionals | Data current as of March 2026

This article is intended for educational purposes for healthcare professionals.

PsychoPharmRef Newsletter

Stay current with AI-assisted reviews of new psychiatric research, FDA approvals, and guideline updates.